Sanofi-Aventis's Lantus insulin linked to cancer risk in studies
This article was originally published in Scrip
Sanofi-Aventis's long-acting (once-daily) insulin analogue Lantus (insulin glargine), one of its best-selling drugs, has been linked to an increased risk of cancer compared with human insulin in analysis of data from patient registries in several European countries, and while the data is inconclusive, there is a case to answer experts said. They added that Lantus was not shown to be more effective than human insulin in achieving glucose control in type 2 diabetics.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.